Abodunrin F, Olson D, Emehinola O, Bestvina C
Ther Adv Med Oncol. 2025; 17:17588359251320280.
PMID: 40012708
PMC: 11863254.
DOI: 10.1177/17588359251320280.
Sun L, Romancik J
J Pers Med. 2025; 15(2).
PMID: 39997328
PMC: 11856678.
DOI: 10.3390/jpm15020051.
Chandora K, Chandora A, Saeed A, Cavalcante L
Cancers (Basel). 2025; 17(3).
PMID: 39941782
PMC: 11815873.
DOI: 10.3390/cancers17030413.
Rees M, Abdallah N, Yohannan B, Gonsalves W
Front Immunol. 2024; 15:1424925.
PMID: 39450163
PMC: 11499143.
DOI: 10.3389/fimmu.2024.1424925.
Zaninelli S, Panna S, Tettamanti S, Melita G, Doni A, DAutilia F
Antibodies (Basel). 2024; 13(3).
PMID: 39311376
PMC: 11417890.
DOI: 10.3390/antib13030071.
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing.
Liao C, Engelberts P, Ioan-Facsinay A, Klip J, Schmidt T, Ruijtenbeek R
Commun Biol. 2024; 7(1):983.
PMID: 39138287
PMC: 11322607.
DOI: 10.1038/s42003-024-06682-9.
Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells.
Al Agrafi F, Gaballa A, Hahn P, Arruda L, Jaramillo A, Witsen M
Oncoimmunology. 2024; 13(1):2379063.
PMID: 39076247
PMC: 11285226.
DOI: 10.1080/2162402X.2024.2379063.
CD28 co-stimulation: novel insights and applications in cancer immunotherapy.
Lotze M, Olejniczak S, Skokos D
Nat Rev Immunol. 2024; 24(12):878-895.
PMID: 39054343
PMC: 11598642.
DOI: 10.1038/s41577-024-01061-1.
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.
Neri P, Leblay N, Lee H, Gulla A, Bahlis N, Anderson K
Nat Rev Clin Oncol. 2024; 21(8):590-609.
PMID: 38961233
DOI: 10.1038/s41571-024-00913-y.
Bispecific and multispecific antibodies in oncology: opportunities and challenges.
Goebeler M, Stuhler G, Bargou R
Nat Rev Clin Oncol. 2024; 21(7):539-560.
PMID: 38822215
DOI: 10.1038/s41571-024-00905-y.
Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations.
Martin-Antonio B, Blanco B, Gonzalez-Murillo A, Hidalgo L, Minguillon J, Perez-Chacon G
Front Immunol. 2024; 15:1386856.
PMID: 38779672
PMC: 11109416.
DOI: 10.3389/fimmu.2024.1386856.
Bispecific T cell engager therapy for refractory rheumatoid arthritis.
Bucci L, Hagen M, Rothe T, Raimondo M, Fagni F, Tur C
Nat Med. 2024; 30(6):1593-1601.
PMID: 38671240
DOI: 10.1038/s41591-024-02964-1.
HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors.
Molloy M, Aaron W, Barath M, Bush M, Callihan E, Carlin K
Mol Cancer Ther. 2024; 23(9):1294-1304.
PMID: 38670552
PMC: 11372363.
DOI: 10.1158/1535-7163.MCT-23-0524.
Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.
Barachini S, Buda G, Petrini I
J Clin Med. 2024; 13(6).
PMID: 38541800
PMC: 10970861.
DOI: 10.3390/jcm13061574.
Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.
Mehrabadi A, Tat M, Alvanegh A, Roozbahani F, Esmaeili Gouvarchin Ghaleh H
Front Immunol. 2024; 15:1343378.
PMID: 38464532
PMC: 10921556.
DOI: 10.3389/fimmu.2024.1343378.
Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager.
Zhou X, Geyer F, Happel D, Takimoto J, Kolmar H, Rabinovich B
Front Immunol. 2024; 15:1323049.
PMID: 38455046
PMC: 10917902.
DOI: 10.3389/fimmu.2024.1323049.
Design and engineering of bispecific antibodies: insights and practical considerations.
Madsen A, Pedersen L, Kristensen P, Goletz S
Front Bioeng Biotechnol. 2024; 12:1352014.
PMID: 38333084
PMC: 10850309.
DOI: 10.3389/fbioe.2024.1352014.
A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023.
Wei J, Zheng H, Dai S, Liu M
Heliyon. 2024; 10(2):e23929.
PMID: 38312701
PMC: 10835268.
DOI: 10.1016/j.heliyon.2023.e23929.
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state.
Van Lint S, Van Parys A, Van Den Eeckhout B, Vandamme N, Plaisance S, Verhee A
Mol Cancer. 2023; 22(1):191.
PMID: 38031106
PMC: 10685570.
DOI: 10.1186/s12943-023-01908-6.
Targeting Prostate Cancer Using Bispecific T-Cell Engagers against Prostate-Specific Membrane Antigen.
Das G, Ptacek J, Havlinova B, Nedvedova J, Barinka C, Novakova Z
ACS Pharmacol Transl Sci. 2023; 6(11):1703-1714.
PMID: 37974624
PMC: 10644396.
DOI: 10.1021/acsptsci.3c00159.